整理 | GLP1减重宝典内容团队诺和诺德今日公布了其2025年第一季度的财务业绩,报告显示,由于战略投资组合决策,公司已于4月停止开发每周服用一次的口服司美格鲁肽片剂。今年早些时候,多家媒体报道称,诺和诺德已向美国食品药品监督管理局(FDA)提交了一份新的申请,申请25毫克口服司美格鲁肽,用于治疗超重和肥胖。这使其成为全球首个寻求监管批准的专门用于减肥的口服GLP-1疗法。然而,该版本采用每日...
Source Link整理 | GLP1减重宝典内容团队诺和诺德今日公布了其2025年第一季度的财务业绩,报告显示,由于战略投资组合决策,公司已于4月停止开发每周服用一次的口服司美格鲁肽片剂。今年早些时候,多家媒体报道称,诺和诺德已向美国食品药品监督管理局(FDA)提交了一份新的申请,申请25毫克口服司美格鲁肽,用于治疗超重和肥胖。这使其成为全球首个寻求监管批准的专门用于减肥的口服GLP-1疗法。然而,该版本采用每日...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.